Sequent Scientific jumps on receiving WHO prequalification approval for Albendazole API
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Sequent Scientific is currently trading at Rs. 168.65, up by 11.30 points or 7.18% from its previous closing of Rs. 157.35 on the BSE.
The scrip opened at Rs. 166.55 and has touched a high and low of Rs. 175.00 and Rs. 165.00 respectively. So far 372135 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 175.00 on 20-Aug-2024 and a 52 week low of Rs. 86.03 on 13-Sep-2023.
Last one week high and low of the scrip stood at Rs. 175.00 and Rs. 133.00 respectively. The current market cap of the company is Rs. 4200.46 crore.
The promoters holding in the company stood at 52.78%, while Institutions and Non-Institutions held 13.76% and 33.46% respectively.
Sequent Scientific has received prequalification (PQ) approval from the World Health Organization (WHO) for Albendazole, Active Pharmaceutical Ingredient (API). This is in partnership with Mepro Pharmaceuticals, who have successfully developed and commercialised the Albendazole Chewable formulation from its WHO PQ approved plant, using its API. Mepro’s Chewable formulation is the first global approval of its kind by the WHO PQ.
Albendazole is a vital medication used to treat a range of parasitic infections, including tapeworm, roundworm, and hookworm infestations, affecting millions globally, particularly in low and middleincome countries. The WHO prequalification recognizes Sequent Scientific’s commitment to stringent international standards in the production of Albendazole API, ensuring efficacy, safety, and quality.
Sequent Scientific is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals.
